EBACW (European Biotech Acquisition) Moat Score: 1/10 (As of Sep. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EBACW European Biotech Acquisition Corp EBACW
22 GF Score
Price $0.52
View Full Analysis

What is European Biotech Acquisition Moat Score?

European Biotech Acquisition EBACW 22 Moat Score is 1 as of Sep. 10, 2026. GuruFocus rates EBACW with a GF Score™ of 22/100.

European Biotech Acquisition has the Moat Score of 1, which implies that the company might have No Moat - Very weak/transient advantages.

European Biotech Acquisition has No Moat: European Biotech Acquisition Corp is a SPAC with no inherent competitive advantages or market leadership. It lacks proprietary technology, brand strength, or regulatory barriers, resulting in a very weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes European Biotech Acquisition might have No Moat - Very weak/transient advantages.

European Biotech Acquisition  (NAS:EBACW) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

European Biotech Acquisition Moat Score Related Terms

EBACW vs CNTQ, LION, MEOA: Moat Score Comparison

For the Shell Companies subindustry, European Biotech Acquisition's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

European Biotech Acquisition Moat Score vs Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, European Biotech Acquisition's Moat Score distribution charts can be found below:

* The bar in red indicates where European Biotech Acquisition's Moat Score falls into.


EBACW
22GF Score
European Biotech Acquisition Corp EBACW
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 1 mean?
European Biotech Acquisition (EBACW) has a Moat Score of 1 as of Sep. 10, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.
Is European Biotech Acquisition's Moat Score too high?
European Biotech Acquisition's current Moat Score is 1. Overall, European Biotech Acquisition has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does European Biotech Acquisition's Moat Score compare to CNTQ and LION?
European Biotech Acquisition's Moat Score of 1 can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Diversified Financial Services company?
A good Moat Score depends on the Diversified Financial Services industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. European Biotech Acquisition's current Moat Score is 1. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is European Biotech Acquisition stock overvalued right now?
European Biotech Acquisition (EBACW) has a current Moat Score of 1. The current Moat Score is 1. European Biotech Acquisition's overall GF Score™ is 22/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For European Biotech Acquisition (EBACW), the current Moat Score is 1 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

European Biotech Acquisition Business Description

Address EPFL Innovation Park Building, Lausanne, CHE, 1015
European Biotech Acquisition Corp is a blank check company.
22GF Score

Get the complete analysis for EBACW

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.52
Price